Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06161935
Other study ID # JCY001
Secondary ID
Status Completed
Phase
First received
Last updated
Start date April 2008
Est. completion date July 2023

Study information

Verified date December 2023
Source Fudan University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of this observational study is to learn about in invasive non-small cell lung cancer patients who underwent pulmonary resection with systematic lymph node dissection from April 2008 to July 2022 . The main question it aims to answer are: determine the situation of zero risk mediastinal lymph metastases and the different lymph node metastatic patterns of tumors with different characteristics. Participants will provide personal information to analyze. and there is not a comparison group.


Recruitment information / eligibility

Status Completed
Enrollment 7067
Est. completion date July 2023
Est. primary completion date July 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - invasive non-small cell lung cancer patients in FUSCC who underwent pulmonary resection with systematic lymph node dissection from April 2008 to July 2022 Exclusion Criteria: - none

Study Design


Intervention

Other:
no intervention
no intervention, it is a retrospective study .

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Fudan University

Outcome

Type Measure Description Time frame Safety issue
Primary The number of participants with no mediastinal lymph metastases after systematic lymph node dissection. We counted the number of participants with no mediastinal lymph metastases after systematic lymph node dissection and tried to determine the situation of zero risk mediastinal lymph metastases after our analyses. 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT04669730 - Baduanjin Exercise on Meridian Energy, Lung Function and Heart Rate Variability in Patients Undergoing Lung Operative. N/A
Recruiting NCT05077709 - IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC Phase 2